Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO 2017 Congress; abstract LBA2_PR.
Congressen en symposia
jan 2017
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
okt 2021 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
jun 2024
mrt 2024
nov 2023
sep 2023